Radiation plus targeted drugs for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that is considered borderline resectable or locally advanced (not spread to distant organs).
- You have received at least 2 months of chemotherapy (like FOLFIRINOX or gemcitabine-based) without your cancer getting worse.
- You are at least 18 years old and able to care for yourself (ECOG 0 or 1).
- Your heart, liver, kidney, and bone marrow function are within certain safe limits.
- You have not been treated with a FAK or RAF/MEK inhibitor before.
- You are not pregnant or breastfeeding, and will use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
This trial studies how well radiation therapy works for pancreatic cancer that is locally advanced (near important blood vessels) and cannot be removed with surgery. It may help shrink or control the cancer when surgery isn’t an option.
This study tests a new approach for locally advanced pancreatic cancer that hasn't spread. It combines precise high-dose radiation with an experimental immunotherapy (PCX12) injected directly into the tumor to see if it's safe and tolerable.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.